BackgroundCheck.run
Search For

David M Sabatini, 5712 Surrey St, Cambridge, MA 02138

Known as:
David D Sabatino David Sabitini Dave Sabatini Marcelo Sabatini Davis Sabatini

David Sabatini Phones & Addresses

12 Surrey St, Cambridge, MA 02138    617-8730895   

1105 Massachusetts Ave, Cambridge, MA 02138    617-8730895   

New Rochelle, NY   

Baltimore, MD   

Providence, RI   

Work

Company: David P. Sabatini, Attorney at Law, P.C. Address:
Get Report
Control this profile

Mentions for David M Sabatini

Career records & work history

Lawyers & Attorneys

David Sabatini Photo 1

David Sabatini - Lawyer

Office:
David P. Sabatini, Attorney at Law, P.C.
Specialties:
Litigation, Criminal Defense, Speeding & Traffic Ticket, DUI & DWI, General Practice, Criminal Defense
ISLN:
904099544
Admitted:
1975
University:
Loyola University, B.S., 1972
Law School:
Valparaiso University, J.D., 1975

David Sabatini resumes & CV records

Resumes

David Sabatini Photo 31

David Sabatini

David Sabatini Photo 32

David Sabatini

Publications & IP owners

Us Patents

Mammalian Proteins That Bind To Fkbp12 In A Rapamycin-Dependent Fashion

US Patent:
6476200, Nov 5, 2002
Filed:
Jun 27, 1994
Appl. No.:
08/265967
Inventors:
David M. Sabatini - Baltimore MD
Mary Lui - Kew Gardens NY
Paul Tempst - New York NY
Solomon H. Snyder - Baltimore MD
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A23J 100
US Classification:
530413, 435 691
Abstract:
A protein complex containing 245 kDa and 35 kDa components, designated RAFT1 and RAFT2 (for Rapamycin And FKBP12 Target) interacts with FKBP12 in a rapamycin-dependent manner. This interaction has the pharmacological characteristics expected from the observed in vivo effects of rapamycin: it occurs at low nanomolar concentrations of rapamycin and is competed by excess FK506. Sequences (330 amino acids total) of tryptic peptides derived from the affinity purified 245 kDa RAFT1 reveals striking homologies to the predicted products of the yeast TOR genes, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2550 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively.

Mammalian Proteins That Bind To Fkbp12 In A Rapamycin-Dependent Fashion

US Patent:
6492106, Dec 10, 2002
Filed:
Sep 14, 1994
Appl. No.:
08/305790
Inventors:
David M. Sabatini - Baltimore MD
Mary Lui - Kew Gardens NY
Paul Tempst - New York NY
Solomon H. Snyder - Baltimore MD
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C12Q 168
US Classification:
435 6, 536 231, 536 234, 536 235, 536 243
Abstract:
A protein complex containing 245 kDa and 35 kDa components, designated RAFT1 and RAFT2 (for apamycin nd KBP12 arget) interacts with FKBP12 in a rapamycin-dependent manner. This interaction has the pharmacological characteristics expected from the observed in vivo effects of rapamycin: it occurs at low nanomolar concentrations of rapamycin and is competed by excess FK506. Sequences (330 amino acids total) of tryptic peptides derived from the affinity purified 245 kDa RAFT1 reveals striking homologies to the predicted products of the yeast TOR genes, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2550 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively.

Reverse Transfection Method

US Patent:
6544790, Apr 8, 2003
Filed:
Sep 18, 2000
Appl. No.:
09/664297
Inventors:
David M. Sabatini - Cambridge MA
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:
C12N 1563
US Classification:
435455, 4353201, 435440, 435 6, 435 721, 435174
Abstract:
A reverse transfection method of introducing DNA of interest into cells and arrays, including microarrays, of reverse transfected cells.

Transfection Method And Uses Related Thereto

US Patent:
6951757, Oct 4, 2005
Filed:
Mar 4, 2003
Appl. No.:
10/379130
Inventors:
David M. Sabatini - Cambridge MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:
C12N015/63
C12N015/85
C12N015/00
US Classification:
435455, 4353201, 435174
Abstract:
The invention features a method of introducing nucleic acid molecules into eukaryotic cells by (a) depositing a nucleic acid molecule-containing mixture onto a surface, (b) affixing the nucleic acid molecule-containing mixture to the surface, and (c) plating eukaryotic cells onto the surface under appropriate conditions for entry of the nucleic acid molecules into the cells.

Mtor Kinase-Associated Proteins

US Patent:
7052870, May 30, 2006
Filed:
Feb 18, 2004
Appl. No.:
10/782244
Inventors:
David M. Sabatini - Cambridge MA, US
Do-Hyung Kim - Cambridge MA, US
Dos D. Sarbassov - Shrewsbury MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:
C12P 21/06
US Classification:
435 691
Abstract:
The invention describes isolated mTOR-associated proteins (“mTOR-APs”) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds which modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation.

Phosphorylation And Regulation Of Akt/Pkb By The Rictor-Mtor Complex

US Patent:
7906308, Mar 15, 2011
Filed:
Jan 27, 2006
Appl. No.:
11/341908
Inventors:
David M. Sabatini - Cambridge MA, US
Dos D. Sarbassov - Shrewsbury MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:
C12N 9/12
C12Q 1/00
C12P 21/06
C12N 15/09
C12N 9/00
A61K 38/43
A61K 39/00
A23J 1/00
US Classification:
435194, 435 4, 435 691, 435 692, 435183, 424 941, 4242771, 530412
Abstract:
In certain aspects, the invention relates to methods for identifying compounds which modulate Akt activity mediated by the rictor-mTOR complex and methods for treating or preventing a disorder that is associated with aberrant Akt activity.

Mtor Kinase-Associated Proteins

US Patent:
8258271, Sep 4, 2012
Filed:
May 17, 2006
Appl. No.:
11/436394
Inventors:
David M. Sabatini - Cambridge MA, US
Do-Hyung Kim - Minneapolis MN, US
Dos D. Sarbassov - Shrewsbury MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:
C07K 14/00
US Classification:
530827
Abstract:
The invention describes isolated mTOR-associated proteins (“mTOR-APs”) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds which modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation.

Soluble Mtor Complexes And Modulators Thereof

US Patent:
8394818, Mar 12, 2013
Filed:
Oct 16, 2009
Appl. No.:
13/124159
Inventors:
Nathanael Gray - Boston MA, US
Jae Won Chang - Boston MA, US
Jianming Zhang - Cambridge MA, US
Carson C. Thoreen - Jamaica Plain MA, US
Seong Woo Anthony Kang - Cambridge MA, US
David M. Sabatini - Cambridge MA, US
Qingsong Liu - Jamaica Plain MA, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:
A61K 31/4375
C07D 471/06
US Classification:
514292, 546 81
Abstract:
The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e. g. , benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.

Amazon

David Sabatini Photo 40

Tor: Target Of Rapamycin (Current Topics In Microbiology And Immunology)

Publisher:
Springer
Binding:
Paperback
Pages:
364
ISBN #:
3642623603
EAN Code:
9783642623608
TOR, the Target of Rapamycin was discovered a little over ten years ago in a genetic screen in S. cerevisiae in search of mutants resistant to the cytostatic effects of the antimycotic, rapamycin. Recent studies have placed TOR at the interface between nutrient sensing and the regulation of major an...
David Sabatini Photo 41

Surfactant-Enhanced Subsurface Remediation: Emerging Technologies (Acs Symposium Series)

Publisher:
American Chemical Society
Binding:
Hardcover
Pages:
312
ISBN #:
0841232253
EAN Code:
9780841232259
Provides a timely and thorough review of surfactant-based remediation technologies. Covers fundamental mechanistic studies to scale-up and process modeling and full-scale field implementation studies. Summarizes the technical, economic, and sociopolitical issues affecting widespread implementation o...
David Sabatini Photo 42

Innovative Subsurface Remediation: Field Testing Of Physical, Chemical, And Characterization Technologies (Acs Symposium Series)

Publisher:
American Chemical Society
Binding:
Hardcover
Pages:
312
ISBN #:
0841235961
EAN Code:
9780841235960
Groundwater is one of the most pervasive environmental problems, and cleaning polluted sites has proven formidable. Remediation efforts are often hindered both by the complexity of the subsurface environment and the difficulty of gathering information on the subsurface. This volume evaluates a selec...
David Sabatini Photo 43

Transport And Remediation Of Subsurface Contaminants: Colloidal, Interfacial, And Surfactant Phenomena (Acs Symposium Series)

Publisher:
American Chemical Society
Binding:
Hardcover
Pages:
252
ISBN #:
0841222231
EAN Code:
9780841222236
Combines a timely review of the current understanding of subsurface contaminant transport and remediation with an insightful discussion of critical issues that demand future consideration. Presents in one volume the results of research from a variety of disciplines, including chemistry, chemical eng...
David Sabatini Photo 44

Subsurface Transport And Fate Processes

Author:
Robert C. Knox, Larry W. Canter, David A. Sabatini
Publisher:
CRC Press
Binding:
Hardcover
Pages:
448
ISBN #:
0873711939
EAN Code:
9780873711937
This book represents the first comprehensive reference volume available on subsurface transport and fate processes. The volume is organized into four sections covering the basics of contaminant properties and how they affect transport and fate, the fundamental processes affecting subsurface transpor...

Isbn (Books And Publications)

Transport And Remediation Of Subsurface Contaminants: Colloidal, Interfacial, And Surfactant Phenomena

Author:
David A. Sabatini
ISBN #:
0841222231

Surfactant-Enhanced Subsurface Remediation: Emerging Technologies

Author:
David A. Sabatini
ISBN #:
0841232253

Innovative Subsurface Remediation: Field Testing Of Physical, Chemical, And Characterization Technologies

Author:
David A. Sabatini
ISBN #:
0841235961

Subsurface Transport And Fate Processes

Author:
David A. Sabatini
ISBN #:
0873711939

Possible Relatives

Damon M Sabatini  Daniel A Sabatini  Dominic Sabatini  Dominick A Sabatini  Donald E Sabatini  Eric M Sabatini  Frank G Sabatini  David Last  David W Johnson  David Stamps 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.